Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

BACKGROUND: In low-income and middle-income countries, affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection. The combination of ravidasvir, a pangenotypic non-structural protein 5A (NS5A) inhibitor, and sofosbuvir has shown efficacy and safety in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrieux-Meyer, Isabelle, Tan, Soek-Siam, Thanprasertsuk, Sombat, Salvadori, Nicolas, Menétrey, Caroline, Simon, François, Cressey, Tim R, Said, Hajjah Rosaida Hj Mohd, Hassan, Muhammad Radzi Abu, Omar, Haniza, Tee, Hoi-Poh, Chan, Wah Kheong, Kumar, Suresh, Thongsawat, Satawat, Thetket, Kanawee, Avihingsanon, Anchalee, Khemnark, Suparat, Yerly, Sabine, Ngo-Giang-Huong, Nicole, Siva, Sasikala, Swanson, Alistair, Goyal, Vishal, Bompart, Francois, Pécoul, Bernard, Murad, Shahnaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767645/
https://www.ncbi.nlm.nih.gov/pubmed/33865507
http://dx.doi.org/10.1016/S2468-1253(21)00031-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767645/
https://www.ncbi.nlm.nih.gov/pubmed/33865507
http://dx.doi.org/10.1016/S2468-1253(21)00031-5

Ejemplares similares